Walter Ageno1, Sylvia Haas2, Jeffrey I Weitz3, Samuel Z Goldhaber4, Alexander G G Turpie5, Shinya Goto6, Pantep Angchaisuksiri7, Joern Dalsgaard Nielsen8, Gloria Kayani9, Karen S Pieper10, Sebastian Schellong11, Henri Bounameaux12, Lorenzo G Mantovani13, Paolo Prandoni14, Ajay K Kakkar15. 1. Department of Medicine and Surgery, University of Insubria, Varese, Italy. 2. Technical University of Munich, Munich, Germany. 3. Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada. 4. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States. 5. Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 6. Department of Medicine (Cardiology), Tokai University School of Medicine, Tokai University, Tokai, Japan. 7. Department of Medicine, Ramathibodi Hospital, Mahidol University, Mahidol, Thailand. 8. Department of Cardiology, Copenhagen University Hospital, Copenhagen University, Copenhagen, Denmark. 9. Thrombosis Research Institute, London, United Kingdom. 10. Department of Statistical Research Science, Duke Clinical Research Institute, Durham, North Carolina, United States. 11. Medical Department 2, Municipal Hospital, Dresden, Germany. 12. Faculty of Medicine, University Hospital of Geneva, University of Geneva, Geneva, Switzerland. 13. University Degli Studi di Milano, Bicocca, Italy. 14. Arianna Foundation on Anticoagulation, Bologna, Italy. 15. Thrombosis Research Institute, University College London, London, United Kingdom.
Abstract
BACKGROUND: Management of venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), varies worldwide. METHODS: The Global Anticoagulant Registry in the FIELD - Venous Thromboembolism (GARFIELD-VTE) is a prospective, observational study of 10,685 patients with objectively diagnosed VTE recruited from May 2014 to January 2017 at 417 sites in 28 countries. All patients are followed for at least 3 years. We describe the baseline characteristics of the study population and their management within 30 days of diagnosis. RESULTS: The median age was 60.2 years; 50.4% were male; 61.7% had DVT and 38.3% had PE ± DVT; and 32.3% were obese (body mass index ≥ 30 kg/m2). The most common risk factors were surgery (12.5%), hospitalization (12.0%) and trauma to the lower limbs (7.8%). At the time of VTE diagnosis, 10.1% had active cancer and 5.7% were chronically immobilized. Treatment for VTE was anticoagulant (AC) therapy alone in 90.9% of patients; 5.1% received thrombolytic and/or surgical/mechanical therapy ± AC and 4.0% received no therapy. Pre-diagnosis, 12.8% received AC therapy alone and 0.2% received thrombolytic and/or surgical/mechanical therapy ± AC. After diagnosis, parenteral AC therapy alone was administered in 17.6% of patients, and it was followed by a direct oral AC (DOAC) in 16.4% or a vitamin K antagonist (VKA) in 26.8%. DOACs alone were prescribed to 32.3% of patients, while 5.9% received VKA alone. CONCLUSION: The initial findings from this global registry highlight the heterogeneity in characteristics and management of VTE patients. Prospective follow-up will reveal the impact of this heterogeneity on outcomes. Georg Thieme Verlag KG Stuttgart · New York.
BACKGROUND: Management of venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), varies worldwide. METHODS: The Global Anticoagulant Registry in the FIELD - Venous Thromboembolism (GARFIELD-VTE) is a prospective, observational study of 10,685 patients with objectively diagnosed VTE recruited from May 2014 to January 2017 at 417 sites in 28 countries. All patients are followed for at least 3 years. We describe the baseline characteristics of the study population and their management within 30 days of diagnosis. RESULTS: The median age was 60.2 years; 50.4% were male; 61.7% had DVT and 38.3% had PE ± DVT; and 32.3% were obese (body mass index ≥ 30 kg/m2). The most common risk factors were surgery (12.5%), hospitalization (12.0%) and trauma to the lower limbs (7.8%). At the time of VTE diagnosis, 10.1% had active cancer and 5.7% were chronically immobilized. Treatment for VTE was anticoagulant (AC) therapy alone in 90.9% of patients; 5.1% received thrombolytic and/or surgical/mechanical therapy ± AC and 4.0% received no therapy. Pre-diagnosis, 12.8% received AC therapy alone and 0.2% received thrombolytic and/or surgical/mechanical therapy ± AC. After diagnosis, parenteral AC therapy alone was administered in 17.6% of patients, and it was followed by a direct oral AC (DOAC) in 16.4% or a vitamin K antagonist (VKA) in 26.8%. DOACs alone were prescribed to 32.3% of patients, while 5.9% received VKA alone. CONCLUSION: The initial findings from this global registry highlight the heterogeneity in characteristics and management of VTEpatients. Prospective follow-up will reveal the impact of this heterogeneity on outcomes. Georg Thieme Verlag KG Stuttgart · New York.
Authors: Kylee L Martens; Simone E Dekker; Megan Crowe; Thomas G DeLoughery; Joseph J Shatzel Journal: Thromb Res Date: 2022-08-19 Impact factor: 10.407
Authors: Olivia Wu; Stephen Morris; Torben Bjerregaard Larsen; Flemming Skjøth; Alex Evans; Kevin Bowrin; Piotr Wojciechowski; Wojciech Margas; Maria Huelsebeck Journal: Cardiovasc Ther Date: 2022-06-09 Impact factor: 3.368
Authors: Synne G Fronas; Camilla T Jørgensen; Anders E A Dahm; Hilde S Wik; Jostein Gleditsch; Nezar Raouf; René Holst; F A Klok; Waleed Ghanima Journal: Blood Adv Date: 2020-10-27
Authors: Ali Al Bshabshe; Wesam Faried Mousa; Mohammed Sultan Alshehri; Mazen Mohammed Saeed Alshahrani; Omar Mohammed Alamri; Fayez Saeed Alshehri; Mohammed Ali AlFlan; Afnan Sultan Alshehri Journal: J Family Med Prim Care Date: 2021-07-02
Authors: Stefano Barco; Luca Valerio; Walter Ageno; Alexander T Cohen; Samuel Z Goldhaber; Beverley J Hunt; Alfonso Iorio; David Jimenez; Frederikus A Klok; Nils Kucher; Seyed Hamidreza Mahmoudpour; Saskia Middeldorp; Thomas Münzel; Vicky Tagalakis; Aaron M Wendelboe; Stavros V Konstantinides Journal: Lancet Respir Med Date: 2020-10-12 Impact factor: 30.700
Authors: Walter Ageno; Ivan B Casella; Kok Han Chee; Sebastian Schellong; Sam Schulman; Daniel E Singer; Marc Desch; Wenbo Tang; Isabelle Voccia; Kristina Zint; Samuel Z Goldhaber Journal: J Thromb Thrombolysis Date: 2021-04 Impact factor: 2.300